Screening and verification of proteins that interact with HSPC238

Jia-Yu Tan1, Jing-Lin Chen2, Xiang Huang2

  • 1Central Intensive Care Unit, Bo'ai Hospital of Zhongshan City Affiliated with Southern Medical University, Zhongshan 528403, P.R. China.

Oncology Reports
|September 24, 2015
PubMed

Insights

HSPC238, a tumor suppressor, interacts with HMOX1, RPS27A, ubiquitin B, and MT2A. These interactions, potentially via the ubiquitin-proteasome pathway, may explain how HSPC238 inhibits hepatocellular carcinoma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • HSPC238 is a novel tumor suppressor with E3 ubiquitin ligase activity.
  • HSPC238 is downregulated in hepatocellular carcinoma (HCC) and inhibits cancer cell proliferation and invasion.
  • The molecular mechanisms of HSPC238's tumor-suppressive function remain largely unelucidated.

Purpose of the Study:

  • To identify proteins that physically interact with HSPC238.
  • To elucidate the molecular mechanisms underlying HSPC238's role in hepatocellular carcinoma.

Main Methods:

  • Yeast two-hybrid screening using a human fetal liver cDNA library.
  • Construction of a bait vector with human HSPC238 gene cDNA.
  • Validation of protein interactions using multiple reporter gene assays, confocal microscopy, co-immunoprecipitation, and pull-down assays.

Main Results:

  • Yeast two-hybrid screening identified 124 positive clones.
  • 12 candidate interacting genes were identified through reporter gene assays.
  • HMOX1, RPS27A, ubiquitin B, and MT2A were validated as interacting proteins with HSPC238.
  • These interacting proteins are implicated in tumor development and the ubiquitin-proteasome pathway.

Conclusions:

  • HSPC238 interacts with HMOX1, RPS27A, ubiquitin B, and MT2A.
  • These interactions likely occur through the ubiquitin-proteasome pathway.
  • Identifying these interacting proteins provides insights into novel mechanisms of HSPC238-mediated tumor suppression in HCC.